The Pulmonary Hypertension Association (PHA) provides this tool to help participants learn more about research ongoing in PH. Use the filters below to narrow the search results to fit your personal needs. Each listing describes current research, who qualifies to participate, and whom to contact for information.
No personal information can be collected through this tool. The information presented on the PHA Clinical Trials page has been obtained directly from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH). PHA recommends that you use the information in this resource to begin a conversation with your PH specialist about whether or not participating in research is right for you.
mTOR activation has been shown to be relevant in the development and progression of pulmonary
hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension
in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in
Selexipag is available for the treatment of pulmonary arterial hypertension (PAH) in adults
in various countries. The efficacy of selexipag to delay disease progression was shown in a
previous pivotal study conducted in 1156 adult patients with PAH. Given the similarities in
the functional changes of PAH in children and adults, it is expected that children suffering
from PAH could benefit from treatment with selexipag. The aim of the present study is to
confirm the doses of selexipag to be used in pediatric patients with PAH older than 2 years.
To fulfill this aim, blood levels of selexipag (pharmacokinetic assessments) as well as the
Aim of Work:
The aim of this randomized, double-blinded, study is to compare between three modes of
ventilation during cardiopulmonary bypass in pediatric patients with pulmonary hypertension
undergoing corrective cardiac surgeries.
The hypothesis of the present study is that high frequency low volume positive pressure
ventilation is better than continous positive airway pressure (CPAP)and passive deflation on
direct PAP (pulmonary artery pressure ) reading and immediate oxygenation after
cardiopulmonary bypass CPB in pediatric patients undergoing cardiac surgeries for congenital
This is a prospective, longitudinal, observational study of free-living activity trackers and
patient reported outcomes to test the hypothesis that daily activity will have stronger
prognostic value than 6MWD in patients with pulmonary hypertension after 12 weeks.
The main objective of this study is to analyze the survival of a cohort of patients admitted
for acute decompensation of pulmonary arterial hypertension or postembolic pulmonary
hypertension and to establish the prognostic value of biomarkers.
This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose
TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial
hypertension.The trial is expected to include 60 patients, divided into 6 groups, according
to 1:1:1:1:1:1 into the placebo group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil
tablets 20mg, 40mg group, each group 10 cases.
This prospective, observational, multicenter, patient registry will follow patients who are
receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram
A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed,
inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term
oxygen therapy followed by a long term extension study
This is a first-in-human (FIH), single-blind, placebo-controlled, single-centre study
designed to assess the safety and tolerability of PDNO in healthy male and female subjects.
In addition, the exposure of 1,2 propanediol (PD) will be evaluated.
The study will be conducted in 2 parts:
Part I: single ascending dose (SAD), 7 cohorts, 30 minutes intravenous (iv) infusion of
placebo followed by 1 hour iv infusion of PDNO to assess safety, tolerability and PD exposure
in healthy male and female subjects.
Part II: ascending doses of PDNO in 2 cohorts, 30 minutes iv infusion of placebo followed by
3 ascending doses of PDNO in...
Pulmonary Arterial Hypertension or PAH is a progressive condition for which there is no cure.
Even with substantial pharmacologic advances in the modern treatment era, survival still
remains unacceptably poor, as reported in large PAH registries. Preclinical studies suggest
that the administration of allogeneic CDCs have the potential to reduce adverse arteriolar
remodeling in PAH which was the basis for the approved investigational new drug (IND). The
use of CDCs as an adjunctive therapy in patients comprising 4 sub-groups of patients with PAH
in which inflammation and immune dysfunction are key pathophysiologic drivers of PAH.